

istrative Code, §355.307, relating to Reimbursement Setting Methodology, in accordance with Rider 40 so that the rate for all facilities in this special reimbursement class of nursing facilities will be based upon the unadjusted federal per diem rate for rural Medicare skilled nursing facilities for the most recent federal fiscal year. HHSC also intends to propose a new rule as part of this methodological revision.

Rider 40 appropriates funds for state fiscal year 2022-23 to support the rate increases for Pediatric Long-term Facilities.

**Briefing Packet.** A briefing packet describing the proposed payment rates is available at <https://rad.hhs.texas.gov/proposed-rate-packets>. Interested parties may also obtain a copy of the briefing packet prior to the hearing by contacting the HHSC Provider Finance Department by telephone at (512) 424-6637, by fax at (512) 730-7475, or by e-mail at [PF-DLTSS@hhs.texas.gov](mailto:PF-DLTSS@hhs.texas.gov).

**Written Comments.** Written comments regarding the proposed payment rates may be submitted in lieu of, or in addition to, oral testimony until 5:00 p.m. the day of the hearing. Written comments may be sent by U.S. mail to the Texas Health and Human Services Commission, Attention: Provider Finance, Mail Code H-400, P.O. Box 149030, Austin, Texas 78714-9030; by fax to Provider Finance at (512) 730-7475; or by email to [PF-DLTSS@hhs.texas.gov](mailto:PF-DLTSS@hhs.texas.gov). In addition, written comments may be sent by overnight mail or hand delivered to Texas Health and Human Services Commission, Attention: Provider Finance, Mail Code H-400, North Austin Complex Building, 4601 W. Guadalupe St., Austin, Texas 78751.

**Preferred Communication.** During the current state of disaster due to COVID-19, physical forms of communication are checked with less frequency than during normal business operations. For the quickest response, please use email or phone, if possible, for communication with HHSC related to this public hearing.

TRD-202102353

Karen Ray

Chief Counsel

Texas Health and Human Services Commission

Filed: June 16, 2021



## Notice of Public Hearing on Proposed Rate Actions for HCS and TxHmL and the FY 2020-21 Quarter 4 Biennial Fee Review

**Hearing.** The Texas Health and Human Services Commission (HHSC) will conduct a public hearing on July 14, 2021, at 9:00 a.m., to receive public comments on proposed rate actions for the fiscal year 2020-21 quarter 4 biennial fee review and Home and Community-Based Waiver (HCS) and Texas Home Living Waiver (TxHmL) respite and day habilitation services.

Due to the declared state of disaster stemming from COVID-19, this hearing will be conducted online only. Physical entry to the hearing will not be permitted. Join the meeting from your computer, tablet, or smartphone at the following link:

<https://attendee.gotowebinar.com/register/1792567207796862733>

After registering, you will receive a confirmation email containing information about joining the webinar. You can also dial in using your phone at (562) 247-8422, access code 688-125-053.

If you are new to GoToWebinar, download the GoToMeeting app at <https://global.gotomeeting.com/install/626873213> before the hearing starts.

The hearing will be held in compliance with Texas Human Resources Code §32.0282, which requires public notice of and hearings on proposed Medicaid reimbursement rates. HHSC will archive the public hearing; the archive can be accessed on-demand after the hearing at <https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings>.

**Proposal.** HHSC proposes to include two groups of rate updates during the rate hearing.

As part of the biennial fee review, which includes existing services with rates that are reviewed at least once every two years, HHSC is proposing rates for Emergency Response Services and for Preadmission Screening and Resident Review Intellectual and Developmental Disabilities Habilitative Specialized Services, proposed to be effective September 1, 2021.

HHSC is also proposing rates for in-home and out-of-home day habilitation and in-home and out-of-home respite in HCS and TxHmL to comply with Electronic Visit Verification requirements. The HCS and TxHmL rates are proposed to be effective August 1, 2021.

**Methodology and Justification.** The proposed payment rates for these topics are guided by the following sections in Title 1 of the Texas Administrative Code: §355.510, related to the Reimbursement Methodology for Emergency Response Services (ERS); §355.315 related to the Reimbursement Methodology for Preadmission Screening and Resident Review (PASRR) Specialized Services; §355.723, related to the Reimbursement Methodology for Home and Community-Based Services and Texas Home Living Programs; and §355.9090, related to the Reimbursement Methodology for Community First Choice.

The billing codes for day habilitation and respite in HCS and TxHmL are being modified to comply with EVV requirements, and the proposed rates will follow these modified billing codes.

**Briefing Packet.** A briefing packet describing the proposed payment rates will be available at <https://rad.hhs.texas.gov/proposed-rate-packets> on or after June 30, 2021. Interested parties may obtain a copy of the briefing packet before the hearing by contacting the HHSC Provider Finance Department by telephone at (512) 424-6637; by fax at (512) 730-7475; or by e-mail at [pf-dltss@hhs.texas.gov](mailto:pf-dltss@hhs.texas.gov).

**Written Comments.** Written comments regarding the proposed payment rates may be submitted in lieu of, or in addition to, oral testimony until 5:00 p.m. the day of the hearing. Written comments may be sent by U.S. mail to the Texas Health and Human Services Commission, Attention: Provider Finance, Mail Code H-400, P.O. Box 149030, Austin, Texas 78714-9030; by fax to Provider Finance at (512) 730-7475; or by email to [pf-dltss@hhs.texas.gov](mailto:pf-dltss@hhs.texas.gov). In addition, written comments may be sent by overnight mail or hand-delivered to Texas Health and Human Services Commission, Attention: Provider Finance, Mail Code H-400, North Austin Complex, 4601 W Guadalupe St., Austin, Texas 78751.

**Preferred Communication.** During the current state of disaster due to COVID-19, physical forms of communication are checked with less frequency than during normal business operations. For the quickest response, please use email or phone, if possible, for communication with HHSC related to this public hearing.

TRD-202102350

Karen Ray

Chief Counsel

Texas Health and Human Services Commission

Filed: June 16, 2021



**Department of State Health Services**

Amendment Placing Five Fentanyl-related Substances into Schedule I; Temporarily Placing Bupropion into Schedule I, and Permanently Placing Lemborexant into Schedule IV

The Drug Enforcement Administration issued a final rule placing cyclopentyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylcyclopentanecarboxamide), isobutyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide), *p*-chloroisobutyryl fentanyl (*N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide), *p*-methoxybutyryl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide), and valeryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible, into Schedule I of the Controlled Substances Act. This final rule was published in the November 25, 2020 issue of the *Federal Register*, Volume 85, Number 228, pages 75231-75235 and was effective November 25, 2020.

The Acting Administrator of the Drug Enforcement Administration issued an order temporarily placing bromphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2*H*-benzo[d]imidazol-2-one), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible into Schedule I of the Controlled Substances Act. This order was published in the March 1, 2021 issue of the *Federal Register*, Volume 86, Number 38, pages 11862-11867, and was effective March 1, 2021. This action was based on the following:

1. Bromphine has a high potential for abuse;
2. Bromphine has no currently accepted medical use in treatment in the United States; and,
3. Bromphine has a lack of accepted safety for use under medical supervision.

The Drug Enforcement Administration issued a final rule adopting, without change, an interim final rule placing lemborexant ((1*R*,2*S*)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-*N*-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in Schedule IV of the Controlled Substances Act.

This final rule was published in the March 3, 2021 issue of the *Federal Register*, Volume 86, Number 40, pages 12257-12260 and was effective March 3, 2021.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the *Federal Register*. In the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substances cyclopentyl fentanyl, isobutyryl fentanyl, *p*-chloroisobutyryl fentanyl, *p*-methoxybutyryl fentanyl and valeryl fentanyl be placed into schedule I; bromphine be placed temporarily into schedule I; and lemborexant be permanently placed into schedule IV.

### **-Schedule I opiates**

The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation:

- (1) Acetyl- $\alpha$ -methylfentanyl (*N*-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-*N*-phenylacetamide);
- (2) Acetylmethadol;
- (3) Acetyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide);
- (4) Acryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacrylamide) (Other name: acryloylfentanyl);
- (5) AH-7921 (3,4-dichloro-*N*-[1-(dimethylamino)cyclohexymethyl]benzamide);
- (6) Allylprodine;
- (7) Alphacetylmethadol (except levo- $\alpha$ -cetylmethadol, levo- $\alpha$ -acetylmethadol, levomethadyl acetate, or LAAM);
- (8)  $\alpha$ -Methylfentanyl or any other derivative of fentanyl;
- (9)  $\alpha$ -Methylthiofentanyl (*N*-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl] *N*-phenylpropanamide);
- (10) Benzethidine;
- (11)  $\beta$ -Hydroxyfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-*N*-phenylpropanamide);
- (12)  $\beta$ -Hydroxy-3-methylfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-*N*-phenylpropanamide);

- (13)  $\beta$ -Hydroxythiofentanyl (Other names: *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylpropanamide; *N*-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidnyl]-*N*-phenylpropanamide);
- (14) Betaprodine;
- (15) Butyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide);
- (16) Clonitazene;
- (17) Crotonyl fentanyl ((*E*)-*N*-(1-Phenethylpiperidin-4-yl)-*N*-phenylbut-2-enamide);
- \*(18) Cyclopentyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-Phenylcyclopentanecarboxamide);
- (19) Cyclopropyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylcyclopropanecarboxamide);
- (20) Diampromide;
- (21) Diethylthiambutene;
- (22) Difenoazin;
- (23) Dimenoxadol;
- (24) Dimethylthiambutene;
- (25) Dioxaphetyl butyrate;
- (26) Dipipanone;
- (27) Ethylmethylthiambutene;
- (28) Etonitazene;
- (29) Etoxadine;
- (30) 4-Fluoroisobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide) (Other name: *p*-fluoroisobutyryl fentanyl);
- (31) Furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-2-carboxamide);
- (32) Furethidine;
- (33) Hydroxypethidine;
- \*(34) Isobutyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide)
- (35) Ketobemidone;
- (36) Levophenacetylmorphan;
- (37) Meprodine;
- (38) Methadol;
- (39) Methoxyacetyl fentanyl (2-methoxy-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide);
- (40) 3-Methylfentanyl (*N*-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-*N*-phenylpropanamide);
- (41) 3-Methylthiofentanyl (*N*-[3-methyl-1-(2-thienyl)ethyl-4-piperidyl]-*N*-phenylpropanamide);
- (42) Moramide;
- (43) Morpheridine;
- (44) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

- (45) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
- (46) Noracymethadol;
- (47) Norlevorphanol;
- (48) Normethadone;
- (49) Norpipanone;
- (50) Ocfentanil (*N*-(2-fluorophenyl)-2-methoxy-*N*-(1-phenethylpiperidin-4-yl)acetamide);
- (51) *o*-Fluorofentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl);
- \*(52) *p*-Chloroisobutyryl fentanyl (*N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);
- (53) *p*-Fluorobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide);
- (54) *p*-Fluorofentanyl (*N*-(4-fluorophenyl)-*N*-[1-(2-phenethyl)-4 piperidinyl]propanamide);
- \*(55) *p*-Methoxybutyryl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide);
- (56) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- (57) Phenadoxone;
- (58) Phenampromide;
- (59) Phencyclidine;
- (60) Phenomorphan;
- (61) Phenoperidine;
- (62) Piritramide;
- (63) Proheptazine;
- (64) Properidine;
- (65) Propiram;
- (66) Tetrahydrofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenyltetrahydrofuran-2-carboxamide);
- (67) Thiofentanyl (*N*-phenyl-*N*-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
- (68) Tilidine;
- (69) Trimeperidine;
- (70) U-47700 (3,4-dichloro-*N*-[2-(dimethylamino)cyclohexyl]-*N*-methylbenzamide; and,
- \*(71) Valeryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide).

**-Schedule I temporarily listed substances subject to emergency scheduling by the U.S. Drug Enforcement Administration.**

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's salts, isomers,

esters, and ethers and salts of isomers, esters, and ethers if the existence of the salts, isomers, esters, and ethers and salts of isomers, esters, and ethers is possible within the specific chemical designation:

(1) Fentanyl-related substances.

(1-1) Fentanyl-related substance means any substance not otherwise listed under another Administration Controlled Substance Code Number, and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications:

(1-1-1) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;

(1-1-2) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups;

(1-1-3) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;

(1-1-4) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or

(1-1-5) Replacement of the *N*-propionyl group by another acyl group.

(1-2) This definition includes, but is not limited to, the following substances:

(1-2-1) *N*-(1-(2-Fluorophenethyl)piperidin-4-yl)-*N*-(2-fluorophenyl)propionamide (Other name: 2'-fluoro-*o*-fluorofentanyl);

(1-2-2) *N*-(2-Methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide (Other name: *o*-methyl acetylfentanyl);

(1-2-3) *N*-(1-Phenethylpiperidin-4-yl)-*N*,3-diphenylpropanamide (Other names: β'-phenyl fentanyl; hydrocinnamoyl fentanyl); and,

(1-2-4) *N*-(1-Phenethylpiperidin-4-yl)-*N*-phenylthiophene-2-carboxamide (Other name: thiofuranyl fentanyl).

(2) Naphthalen-1-yl-1-(5-fluoropentyl)-1*H*-indole-3-carboxylate (Other names: NM2201; CBL2201);

(3) *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide (Other name: 5F-AB-PINACA);

(4) 1-(4-Cyanobutyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-3-carboxamide (Other names: 4-CN-CUMYL-BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL-BINACA; CUMYL-4CN-BINACA; SGT-78);

(5) Methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3-methylbutanoate (Other names: MMB-CHMICA; AMB-CHMICA);

- (6) 1-(5-Fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-pyrrolo[2,3-*b*]pyridine-3-carboxamide (Other name: 5F-CUMYL-P7AICA);
- (7) *N*-ethylpentylone (Other names: ephylone, 1-(1,3-benzodioxil-5-yl)-2-(ethylamino)-pentan-1-one);
- (8) Ethyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: 5F-EDMB-PINACA);
- (9) Methyl 2-(1-(5-fluoropentyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate (Other name: 5F-MDMB-PICA);
- (10) *N*-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide (Other names: FUB-AKB48; FUB-APINACA; AKB48 *N*-(4-FLUOROBENZYL));
- (11) 1-(5-Fluoropentyl)-*N*-(2-phenylpropan-2-yl)-1*H*-indazole-3-carboxamide (Other names: 5F-CUMYL-PINACA; SGT-25);
- (12) (1-(4-Fluorobenzyl)-1*H*-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other name: FUB-144);
- (13) *N*-Ethylhexedrone (Other name: 2-(ethylamino)-1-phenylhexan-1-one);
- (14)  $\alpha$ -Pyrrolidinohexanophenone (Other names:  $\alpha$ -PHP;  $\alpha$ -pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
- (15) 4-Methyl- $\alpha$ -ethylaminopentiophenone (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);
- (16) 4-Methyl- $\alpha$ -pyrrolidinohexiophenone (Other names: MPHP, 4'-methyl- $\alpha$ -pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
- (17)  $\alpha$ -Pyrrolidinoheptaphenone (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
- (18) 4-Chloro- $\alpha$ -pyrrolidinovalerophenone (Other names: 4-chloro- $\alpha$ -PVP; 4-chloro- $\alpha$ -pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
- (19) *N,N*-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine (Other names: isotonitazene; *N,N*-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1*H*-benzimidazole-1-ethanamine);
- and,
- \*(20) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2*H*-benzo[d]imidazol-2-one (Other name: 1-[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-2*H*-benzimidazol-2-one)

#### **-Schedule IV depressants**

Except as provided by the Texas Controlled Substances Act, Health and Safety Code, Section 481.033, a material, compound, mixture, or preparation that contains any quantity of the following substances or any of the substance's salts, isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation having a potential for abuse associated with a depressant effect on the central nervous system:



- (1) Alfaxalone (5 $\alpha$ -pregnan-3 $\alpha$ -ol-11,20-dione);
- (2) Alprazolam;
- (3) Barbitol;
- (4) Brexanolone (3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one) (Other name: allopregnanolone);
- (5) Bromazepam;
- (6) Camazepam;
- (7) Chloral betaine;
- (8) Chloral hydrate;
- (9) Chlordiazepoxide;
- (10) Clobazam;
- (11) Clonazepam;
- (12) Clorazepate;
- (13) Clotiazepam;
- (14) Cloxazolam;
- (15) Delorazepam;
- (16) Diazepam;
- (17) Dichloralphenazone;
- (18) Estazolam;
- (19) Ethchlorvynol;
- (20) Ethinamate;
- (21) Ethyl loflazepate;
- (22) Fludiazepam;
- (23) Flunitrazepam;
- (24) Flurazepam;
- (25) Fospropofol;
- (26) Halazepam;
- (27) Haloxazolam;
- (28) Ketazolam;
- \*(29) Lemborexant;
- (30) Loprazolam;
- (31) Lorazepam;
- (32) Lormetazepam;
- (33) Mebutamate;
- (34) Medazepam;
- (35) Meprobamate;
- (36) Methohexital;
- (37) Methylphenobarbital (mephobarbital);
- (38) Midazolam;
- (39) Nimetazepam;
- (40) Nitrazepam;
- (41) Nordiazepam;
- (42) Oxazepam;

- (43) Oxazolam;
- (44) Paraldehyde;
- (45) Petrichloral;
- (46) Phenobarbital;
- (47) Pinazepam;
- (48) Prazepam;
- (49) Quazepam;
- (50) Remimazolam;
- (51) Suvorexant;
- (52) Temazepam;
- (53) Tetrazepam;
- (54) Triazolam;
- (55) Zaleplon;
- (56) Zolpidem; and
- (57) Zopiclone.

TRD-202102317  
 Barbara L. Klein  
 General Counsel  
 Department of State Health Services  
 Filed: June 14, 2021



**Texas Lottery Commission**

Scratch Ticket Game Number 2317 "DOUBLE YOUR MONEY"

1.0 Name and Style of Scratch Ticket Game.

A. The name of Scratch Ticket Game No. 2317 is "DOUBLE YOUR MONEY". The play style is "key number match".

1.1 Price of Scratch Ticket Game.

A. The price for Scratch Ticket Game No. 2317 shall be \$5.00 per Scratch Ticket.

1.2 Definitions in Scratch Ticket Game No. 2317.

A. Display Printing - That area of the Scratch Ticket outside of the area where the overprint and Play Symbols appear.

B. Latex Overprint - The removable scratch-off covering over the Play Symbols on the front of the Scratch Ticket.

C. Play Symbol - The printed data under the latex on the front of the Scratch Ticket that is used to determine eligibility for a prize. Each Play Symbol is printed in Symbol font in black ink in positive except for dual-image games. The possible black Play Symbols are: 01, 02, 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, \$\$ SYMBOL, MONEY BAG SYMBOL, \$5.00, \$10.00, \$20.00, \$50.00, \$100, \$500, \$1,000 and \$100,000.

D. Play Symbol Caption - The printed material appearing below each Play Symbol which explains the Play Symbol. One caption appears under each Play Symbol and is printed in caption font in black ink in positive. The Play Symbol Caption which corresponds with and verifies each Play Symbol is as follows: